November 11, 2020 08:00 AM EST

Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors

Nicole DeFeudis

Editor

A year after Cirius Therapeutics’ lead NASH drug flopped in a large Phase IIb trial, the biotech’s chief business and financial officer Brian Farmer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

New fund will pressure flailing biotechs, as investor frustration boils over

RFK Jr. touts CMS program testing new ways to pay for sickle cell disease treatment

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Small biotech Inipharm lands $35M to take new NASH ap­proach, di­verg­ing from RNAi com­peti­tors

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors